Advertisement
Screener

VERTEX PHARMACEUTICALS INC / MA (VRTX) Restructuring Charges

2.8 / 5 stars · 68/120 Roast Me

VERTEX PHARMACEUTICALS INC / MA Restructuring Charges

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Restructuring Charges of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.

Discontinued › Expense Statement › Operating Expenses

us-gaap:RestructuringCharges · last filed 2021-02-11

  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for the quarter ending 2019-12-31 was $0.00.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for the quarter ending 2019-06-30 was $0.00.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for fiscal 2020 was $0.00.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for fiscal 2019 was $0.00.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for fiscal 2018 was -$184.00K, a 101.29% decline from fiscal 2017.
  • VERTEX PHARMACEUTICALS INC / MA restructuring charges for fiscal 2017 was $14.25M, a 1028.84% increase from fiscal 2016.
Period endRestructuring Charges 3 monthRestructuring Charges 3 month as first filedRestructuring Charges 6 monthRestructuring Charges 9 monthRestructuring Charges 12 monthRestructuring Charges 84 monthRestructuring Charges 96 monthRestructuring Charges 108 month
2020-12-31$0.00
10-K · filed 2021-02-11
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11
$0.00
derived: sum of 2 quarters · filed 2021-02-11
$0.00
derived: sum of 3 quarters · filed 2021-02-11
$0.00
10-K · filed 2021-02-11
2019-09-30$0.00
10-Q · filed 2019-10-31
$0.00
derived: sum of 2 quarters · filed 2019-10-31
$0.00
10-Q · filed 2019-10-31
-$4.00K
derived: sum of 4 quarters · filed 2020-02-13
2019-06-30$0.00
10-Q · filed 2019-08-01
$0.00
10-Q · filed 2019-08-01
-$4.00K
derived: sum of 3 quarters · filed 2020-02-13
$170.00K
derived: sum of 4 quarters · filed 2020-02-13
2019-03-31$0.00
10-Q · filed 2019-05-01
-$4.00K
derived: sum of 2 quarters · filed 2020-02-13
$170.00K
derived: sum of 3 quarters · filed 2020-02-13
$108.00K
derived: sum of 4 quarters · filed 2020-02-13
2018-12-31-$4.00K
10-K · filed 2020-02-13
$4.00K
10-K · filed 2019-02-13
$170.00K
derived: sum of 2 quarters · filed 2020-02-13
$108.00K
derived: sum of 3 quarters · filed 2020-02-13
-$184.00K
10-K · filed 2021-02-11
2018-09-30$174.00K
10-K · filed 2020-02-13
-$174.00K
10-Q · filed 2018-10-25
$112.00K
derived: sum of 2 quarters · filed 2020-02-13
-$188.00K
10-Q · filed 2019-10-31
$575.00K
derived: sum of 4 quarters · filed 2020-02-13
2018-06-30-$62.00K
10-K · filed 2020-02-13
$62.00K
10-Q · filed 2018-07-26
-$14.00K
10-Q · filed 2019-08-01
$401.00K
derived: sum of 3 quarters · filed 2020-02-13
$738.00K
derived: sum of 4 quarters · filed 2020-02-13
2018-03-31$76.00K
10-K · filed 2020-02-13
-$76.00K
10-Q · filed 2018-04-27
$463.00K
derived: sum of 2 quarters · filed 2020-02-13
$800.00K
derived: sum of 3 quarters · filed 2020-02-13
$4.32M
derived: sum of 4 quarters · filed 2020-02-13
2017-12-31$387.00K
10-K · filed 2019-02-13
$724.00K
derived: sum of 2 quarters · filed 2019-02-13
$4.25M
derived: sum of 3 quarters · filed 2019-02-13
$14.25M
10-K · filed 2020-02-13
2017-09-30$337.00K
10-K · filed 2019-02-13
$3.86M
derived: sum of 2 quarters · filed 2019-02-13
$13.86M
10-Q · filed 2018-10-25
$14.08M
derived: sum of 4 quarters · filed 2019-02-13
2017-06-30$3.52M
10-K · filed 2019-02-13
$13.52M
10-Q · filed 2018-07-26
$13.75M
derived: sum of 3 quarters · filed 2019-02-13
$13.75M
derived: sum of 4 quarters · filed 2019-02-13
2017-03-31$10.00M
10-K · filed 2019-02-13
$10.22M
derived: sum of 2 quarters · filed 2019-02-13
$10.23M
derived: sum of 3 quarters · filed 2019-02-13
$10.57M
derived: sum of 4 quarters · filed 2019-02-13
2016-12-31$224.00K
10-K · filed 2018-02-15
$232.00K
derived: sum of 2 quarters · filed 2018-02-15
$575.00K
derived: sum of 3 quarters · filed 2018-02-15
$1.26M
10-K · filed 2019-02-13
2016-09-30$8.00K
10-K · filed 2018-02-15
$351.00K
derived: sum of 2 quarters · filed 2018-02-15
$1.04M
10-Q · filed 2017-10-30
$2.56M
derived: sum of 4 quarters · filed 2018-02-15
2016-06-30$343.00K
10-K · filed 2018-02-15
$1.03M
10-Q · filed 2017-07-28
$2.55M
derived: sum of 3 quarters · filed 2018-02-15
$4.38M
derived: sum of 4 quarters · filed 2018-02-15
2016-03-31$687.00K
10-K · filed 2018-02-15
$2.21M
derived: sum of 2 quarters · filed 2018-02-15
$4.04M
derived: sum of 3 quarters · filed 2018-02-15
$6.17M
derived: sum of 4 quarters · filed 2018-02-15
2015-12-31$1.52M
10-K · filed 2017-02-23
$3.35M
derived: sum of 2 quarters · filed 2017-02-23
$5.48M
derived: sum of 3 quarters · filed 2017-02-23
$2.21M
10-K · filed 2018-02-15
2015-09-30$1.83M
10-K · filed 2017-02-23
$3.95M
derived: sum of 2 quarters · filed 2017-02-23
$682.00K
10-Q · filed 2016-10-31
$4.85M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30$2.13M
10-K · filed 2017-02-23
-$1.14M
10-Q · filed 2016-08-01
$3.02M
derived: sum of 3 quarters · filed 2017-02-23
$43.86M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31-$3.27M
10-K · filed 2017-02-23
$892.00K
derived: sum of 2 quarters · filed 2017-02-23
$41.73M
derived: sum of 3 quarters · filed 2017-02-23
$41.47M
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31$4.16M
10-K · filed 2016-02-16
$45.01M
derived: sum of 2 quarters · filed 2016-02-16
$44.74M
derived: sum of 3 quarters · filed 2016-02-16
$50.92M
10-K · filed 2017-02-23
2014-09-30$40.84M
10-K · filed 2016-02-16
$40.57M
derived: sum of 2 quarters · filed 2016-02-16
$46.76M
10-Q · filed 2015-10-30
$74.42M
derived: sum of 4 quarters · filed 2016-02-16
2014-06-30-$270.00K
10-K · filed 2016-02-16
$5.92M
10-Q · filed 2015-08-04
$33.58M
derived: sum of 3 quarters · filed 2016-02-16
$45.62M
derived: sum of 4 quarters · filed 2016-02-16
2014-03-31$6.19M
10-K · filed 2016-02-16
$33.85M
derived: sum of 2 quarters · filed 2016-02-16
$45.89M
derived: sum of 3 quarters · filed 2016-02-16
$46.67M
derived: sum of 4 quarters · filed 2016-02-16
2013-12-31$27.66M
10-K · filed 2015-02-13
$39.71M
derived: sum of 2 quarters · filed 2015-02-13
$40.48M
derived: sum of 3 quarters · filed 2015-02-13
$40.52M
10-K · filed 2016-02-16
2013-09-30$12.05M
10-K · filed 2015-02-13
$12.82M
derived: sum of 2 quarters · filed 2015-02-13
$12.86M
10-Q · filed 2014-11-06
$13.06M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30$776.00K
10-K · filed 2015-02-13
$815.00K
10-Q · filed 2014-07-31
$1.01M
derived: sum of 3 quarters · filed 2015-02-13
$1.71M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31$39.00K
10-K · filed 2015-02-13
$233.00K
derived: sum of 2 quarters · filed 2015-02-13
$929.00K
derived: sum of 3 quarters · filed 2015-02-13
$1.52M
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31$194.00K
10-K · filed 2014-02-11
$890.00K
derived: sum of 2 quarters · filed 2014-02-11
$1.48M
derived: sum of 3 quarters · filed 2014-02-11
$1.84M
10-K · filed 2015-02-13
$62.48M
10-K · filed 2013-03-01
2012-09-30$696.00K
10-K · filed 2014-02-11
$1.29M
derived: sum of 2 quarters · filed 2014-02-11
$1.65M
10-Q · filed 2013-11-07
$2.64M
derived: sum of 4 quarters · filed 2014-02-11
2012-06-30$594.00K
10-K · filed 2014-02-11
$954.00K
10-Q · filed 2013-08-02
$1.95M
derived: sum of 3 quarters · filed 2014-02-11
$1.53M
derived: sum of 4 quarters · filed 2014-02-11
2012-03-31$360.00K
10-K · filed 2014-02-11
$1.35M
derived: sum of 2 quarters · filed 2014-02-11
$933.00K
derived: sum of 3 quarters · filed 2014-02-11
$1.67M
derived: sum of 4 quarters · filed 2014-02-11
2011-12-31$992.00K
10-K · filed 2013-03-01
$573.00K
derived: sum of 2 quarters · filed 2013-03-01
$1.31M
derived: sum of 3 quarters · filed 2013-03-01
$2.07M
10-K · filed 2014-02-11
$60.63M
10-K · filed 2012-02-22
2011-09-30-$419.00K
10-K · filed 2013-03-01
$322.00K
derived: sum of 2 quarters · filed 2013-03-01
$1.08M
10-Q · filed 2012-11-06
-$1.18M
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30$741.00K
10-K · filed 2013-03-01
$1.50M
10-Q · filed 2012-08-08
-$756.00K
derived: sum of 3 quarters · filed 2013-03-01
$110.00K
derived: sum of 4 quarters · filed 2013-03-01
2011-03-31$760.00K
10-K · filed 2013-03-01
-$1.50M
derived: sum of 2 quarters · filed 2013-03-01
-$631.00K
derived: sum of 3 quarters · filed 2013-03-01
$1.48M
derived: sum of 4 quarters · filed 2013-03-01
2010-12-31-$2.26M
10-K · filed 2012-02-22
-$1.39M
derived: sum of 2 quarters · filed 2012-02-22
$721.00K
derived: sum of 3 quarters · filed 2012-02-22
$1.50M
10-K · filed 2013-03-01
$58.56M
10-K · filed 2011-02-17
2010-09-30$866.00K
10-K · filed 2012-02-22
$2.98M
derived: sum of 2 quarters · filed 2012-02-22
$3.76M
10-Q · filed 2011-11-03
$5.71M
derived: sum of 4 quarters · filed 2012-02-22
2010-06-30$2.11M
10-K · filed 2012-02-22
$2.89M
10-Q · filed 2011-08-09
$4.85M
derived: sum of 3 quarters · filed 2012-02-22
$5.62M
derived: sum of 4 quarters · filed 2012-02-22
2010-03-31$780.00K
10-K · filed 2012-02-22
$2.74M
derived: sum of 2 quarters · filed 2012-02-22
$3.51M
derived: sum of 3 quarters · filed 2012-02-22
$4.62M
derived: sum of 4 quarters · filed 2012-02-22
2009-12-31$1.96M
10-K · filed 2011-02-17
$2.73M
derived: sum of 2 quarters · filed 2011-02-17
$3.84M
derived: sum of 3 quarters · filed 2011-02-17
$6.24M
10-K · filed 2012-02-22
2009-09-30$774.00K
10-K · filed 2011-02-17
$1.88M
derived: sum of 2 quarters · filed 2011-02-17
$4.28M
10-Q · filed 2010-10-28
2009-06-30$1.11M
10-K · filed 2011-02-17
$3.51M
10-Q · filed 2010-08-03
2009-03-31$2.40M
10-K · filed 2011-02-17
2008-12-31$4.32M
10-K · filed 2011-02-17
2003-12-31$91.82M
10-K · filed 2015-02-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64